连续用药时酒石酸麦角胺的全身可用性。
Systemic availability of ergotamine tartrate in continuous medication.
作者信息
Myllylä V V, Ala-Hurula V, Arvela P, Kärki N, Hokkanen E
出版信息
Ups J Med Sci Suppl. 1980;31:20-2.
PMID:6935854
Abstract
There seems to be great individual differences in the bioavailability of ergotamine in continuous use. The great tolerance to ergotamine in some patients using the drug on a daily basis, even in high doses, may be due to the low-bioavailability of ergotamine in these subjects. This may also explain the infrequency of serious complications among migraine patients.
摘要
连续使用时，麦角胺的生物利用度似乎存在很大的个体差异。一些每日使用该药的患者，即使大剂量使用，对麦角胺仍有很大耐受性，这可能是由于这些患者体内麦角胺的生物利用度较低。这也可能解释了偏头痛患者中严重并发症发生率较低的原因。
相似文献
1
Systemic availability of ergotamine tartrate in continuous medication.连续用药时酒石酸麦角胺的全身可用性。
Ups J Med Sci Suppl. 1980;31:20-2.
2
Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.连续三次给药及持续用药期间酒石酸麦角胺的全身可用性。
Eur J Clin Pharmacol. 1979 Nov;16(5):355-60. doi: 10.1007/BF00605636.
3
Systemic availability of ergotamine tartrate in healthy subjects after single and repeated oral doses.单次及重复口服剂量后，健康受试者中酒石酸麦角胺的全身可用性。
Ups J Med Sci Suppl. 1980;31:7-9.
4
Ergotamine tartrate in the treatment of migraine.酒石酸麦角胺治疗偏头痛。
Arch Neurobiol (Madr). 1974;37 SUPPL:317-9.
5
Ergotamine tartrate in migraine and the dangers of overdose.酒石酸麦角胺治疗偏头痛及过量服用的危险
Nurs Times. 1972 Dec 14;68(50):1585.
6
[Migraine caused by ergotamine tartrate dependence].[酒石酸麦角胺依赖性所致偏头痛]
Rev Med Chil. 1992 Jul;120(7):797-9.
7
Migraine: a series of 38 patients treated with ergotamine tablets.偏头痛：一组38例接受麦角胺片治疗的患者。
Med Times. 1971 Dec;99(12):97-102.
8
Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.偏头痛患者静脉注射和肌肉注射麦角胺后的药代动力学。
Eur J Clin Pharmacol. 1982;23(3):235-40. doi: 10.1007/BF00547560.
9
10
Duration of the biological effect of ergotamine tartrate.酒石酸麦角胺生物效应的持续时间。
Adv Neurol. 1982;33:315-9.
Zotero 插件